Watch POAP mints live!

I've met Lily Wong at Bayer's Global DS&AI F2F Meeting

Experienced leader in development, validation, and implementation of clinical trial software and processes

almost 3 years ago

I've met Lily Wong at Bayer's Global DS&AI F2F Meeting POAP image

Lech Garus is attending the DS&AI F2F in Madrid 05.2023. Lech works in the system support as the Senior Systems Manager. Lech comes from Poland and lives in Warsaw. Lech loves paragliding and bread baking.

almost 3 years ago

DS&AI F2F in Madrid 05.2023 POAP image

almost 3 years ago

Loading

Part of the Clinical Trial Technology and strategy group. Bringing new technology and services to our organisation

almost 3 years ago

I've met Julien Kroll at DS&AI Madrid 2023 POAP image

I‘ve met Katrin Dassler at the Bayer DS&AI meeting.

I am Subhead of Systems Support in DS3 and look forward to network with you further.

almost 3 years ago

I‘ve met Katrin Dassler at the Bayer DS&AI meeting. POAP image

almost 3 years ago

Loading

almost 3 years ago

Loading

almost 3 years ago

Loading

almost 3 years ago

Loading

Given the considerable amount of data that is collected throughout clinical trials, it can be asked if this data can be used to improve our understanding of the trial, regardless of outcome. The radiomics pilot seeks to provide a toolkit that is capable of analyzing the different modalities of information found in clinical trials (genome, gene expression, biomarker, clinical information, and imaging information) to derive insights into why a patient may be responding, or why a clinical trial was unsuccessful. The current efforts have focused on clinical trials in oncology, while collaborating with the RED-ONC function. Overall, the project is in its pilot state, and demonstrating a proof of concept, while documenting many challenges and learnings with the development of such a toolkit. Potential directions that could expand this toolbox include deriving the factors that best predict why a patient would stay in a clinical trial, and providing assistance with patient selection of clinical trials. Other potential directions involve suggesting why a particular trial may have been unsuccessful and providing that information back to the drug development team.

almost 3 years ago

I was at the Bayer DS&AI Poster - Radiomics POAP image